Pages that link to "Q43822796"
Jump to navigation
Jump to search
The following pages link to Breakthrough of the year 2013. Cancer immunotherapy (Q43822796):
Displaying 50 items.
- Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer (Q26738539) (← links)
- Towards tumor immunodiagnostics (Q26738691) (← links)
- A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints (Q26738729) (← links)
- The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis (Q26740280) (← links)
- Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives (Q26741009) (← links)
- Clinical development of gene therapy: results and lessons from recent successes (Q26743393) (← links)
- Lymphocyte-activation gene-3, an important immune checkpoint in cancer (Q26746209) (← links)
- Tremelimumab: research and clinical development (Q26752822) (← links)
- Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials (Q26765115) (← links)
- Signaling in T cells - is anything the m(a)TOR with the picture(s)? (Q26767443) (← links)
- Dendritic cell-based vaccine for pancreatic cancer in Japan (Q26768252) (← links)
- Genome-editing Technologies for Gene and Cell Therapy (Q26769662) (← links)
- Targeting adeno-associated virus and adenoviral gene therapy for hepatocellular carcinoma (Q26772315) (← links)
- Current status of immunotherapy (Q26773314) (← links)
- T Lymphocyte-Endothelial Interactions: Emerging Understanding of Trafficking and Antigen-Specific Immunity (Q26774645) (← links)
- Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens (Q26774669) (← links)
- Single-cell analysis tools for drug discovery and development (Q26775754) (← links)
- Nanotechnologies for biomedical science and translational medicine (Q26776376) (← links)
- Tumorsphere as an effective in vitro platform for screening anti-cancer stem cell drugs (Q26777335) (← links)
- Functional Specialization of Skin Dendritic Cell Subsets in Regulating T Cell Responses (Q26777948) (← links)
- Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy (Q26779184) (← links)
- Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy (Q26779938) (← links)
- Targeting Transcriptional Regulators of CD8 T Cell Dysfunction to Boost Anti-Tumor Immunity (Q26782201) (← links)
- Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy (Q26782566) (← links)
- Anti-HBV Drugs: Progress, Unmet Needs, and New Hope (Q26782742) (← links)
- The Promise of Preventive Cancer Vaccines (Q26783742) (← links)
- Potentiality of immunotherapy against hepatocellular carcinoma (Q26784228) (← links)
- Enhancing Cancer Immunotherapy Via Activation of Innate Immunity (Q26796313) (← links)
- Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy (Q26798404) (← links)
- Evolving immunotherapy strategies in urothelial cancer (Q26823557) (← links)
- Universes collide: combining immunotherapy with targeted therapy for cancer (Q26825316) (← links)
- Molecular recognition of gangliosides and their potential for cancer immunotherapies (Q26830588) (← links)
- Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications (Q26996518) (← links)
- Novel immunotherapies for hematologic malignancies (Q27004436) (← links)
- Radiation meets immunotherapy - a perfect match in the era of combination therapy? (Q27005913) (← links)
- Vaccines for the 21st century (Q27007529) (← links)
- The place of targeted agents in the treatment of elderly patients with metastatic colorectal cancer (Q27011366) (← links)
- RNA-guided CRISPR-Cas technologies for genome-scale investigation of disease processes (Q27025675) (← links)
- Surgical Stress Abrogates Pre-Existing Protective T Cell Mediated Anti-Tumor Immunity Leading to Postoperative Cancer Recurrence (Q27345519) (← links)
- Exploiting IL-17-producing CD4 and CD8 T cells to improve cancer immunotherapy in the clinic (Q28075992) (← links)
- Along the Axis between Type 1 and Type 2 Immunity; Principles Conserved in Evolution from Fish to Mammals (Q28083360) (← links)
- Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential (Q28083873) (← links)
- Enhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case study (Q28084489) (← links)
- Supercritical carbon dioxide design strategies: from drug carriers to soft killers (Q28085090) (← links)
- Synthetic Nanoparticles for Vaccines and Immunotherapy (Q28085375) (← links)
- Intradermal vaccination using the novel microneedle device MicronJet600: Past, present, and future (Q28087074) (← links)
- Improving natural killer cell cancer immunotherapy (Q28087719) (← links)
- Development and applications of CRISPR-Cas9 for genome engineering (Q28241526) (← links)
- Dendritic cell-activated cytokine-induced killer cell-mediated immunotherapy is safe and effective for cancer patients >65�years old (Q28468347) (← links)
- Opening the door to innovation (Q28655591) (← links)